Tafinlar/Mekinist (dabrafenib/trametinib)

Numéro de dossier de l’APP: 21500
État des négociations:
Concluded without agreement
Indication(s):
Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease
Promoteur/fabricant:
Novartis Pharmaceuticals Canada Inc.
Numéro de projet de l’ACMTS:
PC0226
Lettre-contrat de l’APP:
Conclusion du processus de négociation: